These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 18574935)
41. Association of 1p/19q Codeletion and Radiation Necrosis in Adult Cranial Gliomas After Proton or Photon Therapy. Acharya S; Robinson CG; Michalski JM; Mullen D; DeWees TA; Campian JL; Chundury A; Bottani B; Hallahan DE; Bradley JD; Huang J Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):334-343. PubMed ID: 29534896 [TBL] [Abstract][Full Text] [Related]
42. High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN). Rodriguez FJ; Schniederjan MJ; Nicolaides T; Tihan T; Burger PC; Perry A Acta Neuropathol; 2015 Apr; 129(4):609-610. PubMed ID: 25720745 [No Abstract] [Full Text] [Related]
43. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Burger PC; Minn AY; Smith JS; Borell TJ; Jedlicka AE; Huntley BK; Goldthwaite PT; Jenkins RB; Feuerstein BG Mod Pathol; 2001 Sep; 14(9):842-53. PubMed ID: 11557779 [TBL] [Abstract][Full Text] [Related]
44. Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas. Li J; Miao N; Liu M; Cui W; Liu X; Li X; Shi X; Qing S; Ma Y; Zhang W; Biekemituofu H Int J Clin Exp Pathol; 2014; 7(12):8609-15. PubMed ID: 25674225 [TBL] [Abstract][Full Text] [Related]
45. 1p/19q chromosome deletions in metastatic oligodendroglioma. Merrell R; Nabors LB; Perry A; Palmer CA J Neurooncol; 2006 Nov; 80(2):203-7. PubMed ID: 16710746 [TBL] [Abstract][Full Text] [Related]
46. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. Polivka J; Polivka J; Repik T; Rohan V; Hes O; Topolcan O Anticancer Res; 2016 Jan; 36(1):471-6. PubMed ID: 26722084 [TBL] [Abstract][Full Text] [Related]
47. Anaplastic oligodendroglial tumors harboring 1p/19q deletion can be successfully treated without radiotherapy. Iwadate Y; Matsutani T; Shinozaki N; Saeki N Anticancer Res; 2011 Dec; 31(12):4475-9. PubMed ID: 22199318 [TBL] [Abstract][Full Text] [Related]
48. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status. Katsetos CD; Del Valle L; Geddes JF; Aldape K; Boyd JC; Legido A; Khalili K; Perentes E; Mörk SJ J Neuropathol Exp Neurol; 2002 Apr; 61(4):307-20. PubMed ID: 11939586 [TBL] [Abstract][Full Text] [Related]
49. MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status. Sherman JH; Prevedello DM; Shah L; Raghavan P; Pouratian N; Starke RM; Lopes MB; Shaffrey ME; Schiff D Acta Neurochir (Wien); 2010 Nov; 152(11):1827-34. PubMed ID: 20711790 [TBL] [Abstract][Full Text] [Related]
50. Co-polysomy of 1p/19q in glial tumors: Retrospective analysis of 221 cases from single center. Kuskucu A; Tuysuz EC; Gurkan S; Demir Z; Yaltirik CK; Ozkan F; Ekici ID; Bayrak OF; Ture U Gene; 2019 Jun; 701():161-168. PubMed ID: 30849537 [TBL] [Abstract][Full Text] [Related]
52. A new der(1;7)(q10;p10) leading to a singular 1p loss in a case of glioblastoma with oligodendroglioma component. Gadji M; Crous-Tsanaclis AM; Mathieu D; Mai S; Fortin D; Drouin R Neuropathology; 2014 Apr; 34(2):170-8. PubMed ID: 24118308 [TBL] [Abstract][Full Text] [Related]
53. Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Lavon I; Zrihan D; Zelikovitch B; Fellig Y; Fuchs D; Soffer D; Siegal T Clin Cancer Res; 2007 Mar; 13(5):1429-37. PubMed ID: 17332285 [TBL] [Abstract][Full Text] [Related]
54. Prediction of anaplastic transformation in low-grade oligodendrogliomas based on magnetic resonance spectroscopy and 1p/19q codeletion status. Bourdillon P; Hlaihel C; Guyotat J; Guillotton L; Honnorat J; Ducray F; Cotton F J Neurooncol; 2015 May; 122(3):529-37. PubMed ID: 25716744 [TBL] [Abstract][Full Text] [Related]
55. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre. Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767 [TBL] [Abstract][Full Text] [Related]
56. Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography. Iwadate Y; Shinozaki N; Matsutani T; Uchino Y; Saeki N J Neurol Neurosurg Psychiatry; 2016 Sep; 87(9):1016-21. PubMed ID: 26848169 [TBL] [Abstract][Full Text] [Related]
57. [Significance and prospects of study on molecular alterations in oligodendrogliomas]. Gresner SM; Liberski PP Neurol Neurochir Pol; 2007; 41(4):333-9. PubMed ID: 17874342 [TBL] [Abstract][Full Text] [Related]
58. Loss of heterozygosity analysis in an anaplastic oligodendroglioma arising after radiation therapy. Hata N; Shono T; Mizoguchi M; Matsumoto K; Guan Y; Nagata S; Hayashi K; Iwaki T; Sasaki T Neurol Res; 2007 Oct; 29(7):723-6. PubMed ID: 17553214 [TBL] [Abstract][Full Text] [Related]
59. New treatment paradigm for patients with anaplastic oligodendroglial tumors. Polivka J; Polivka J; Rohan V; Topolcan O Anticancer Res; 2014 Apr; 34(4):1587-94. PubMed ID: 24692686 [TBL] [Abstract][Full Text] [Related]
60. Prognostic value of 1p, 19q, 9p, 10q, and EGFR-FISH analyses in recurrent oligodendrogliomas. Fallon KB; Palmer CA; Roth KA; Nabors LB; Wang W; Carpenter M; Banerjee R; Forsyth P; Rich K; Perry A J Neuropathol Exp Neurol; 2004 Apr; 63(4):314-22. PubMed ID: 15099021 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]